Kestra Medical Technologies, Ltd.
- KMTS · Nasdaq
- Surgical & Medical Instruments & Apparatus
- Kirkland, WA
- 443 employees
- CIK 0001877184
Updated from SEC filings through
Top things to know
Executives
- Brian Webster President and Chief Executive Officer 10-Q, 2026-09-14
- Vaseem Mahboob Chief Financial Officer 4, 2026-08-11
- Alfred J. Ford Jr Chief Commercial Officer 4, 2026-08-06
- Timothy P. Moran Chief Business Officer 4, 2026-08-03
What leadership is saying
“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%”
Earnings press release (8-K Ex. 99.1), filed September 14, 2026
Kestra Medical Technologies, Ltd. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Kirkland, WA. It trades as KMTS on Nasdaq. Revenue was $95.1M in the fiscal year ending April 30, 2026, +59.0% from the year before. It reported about 443 employees. Brian Webster is President and Chief Executive Officer.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | $95.1M 10-K, 2026-07-14 | $59.8M 10-K, 2026-07-14 | $27.8M 10-K, 2025-07-17 |
| Operating income | -$135M 10-K, 2026-07-14 | -$106M 10-K, 2026-07-14 | -$85.1M 10-K, 2025-07-17 |
| SG&A | $164M 10-K, 2026-07-14 | $115M 10-K, 2026-07-14 | $69.9M 10-K, 2025-07-17 |
| Net income | -$132M 10-K, 2026-07-14 | -$114M 10-K, 2026-07-14 | -$94.1M 10-K, 2025-07-17 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Brian Webster Chief Executive Officer | President and Chief Executive Officer | 10-Q, 2026-09-14 |
| Vaseem Mahboob Chief Financial Officer | Chief Financial Officer | 4, 2026-08-11 |
| Alfred J. Ford Jr | Chief Commercial Officer | 4, 2026-08-06 |
| Timothy P. Moran | Chief Business Officer | 4, 2026-08-03 |
What Kestra Medical Technologies, Ltd. does
We are a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. We have developed and are commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (“SCA”) during vulnerable periods of recovery.
Shares and governance
| Shares outstanding | 59.6 million (as of September 11, 2026) | 10-Q, September 14, 2026 |
|---|---|---|
| Public float | $619M (as of October 31, 2025) | 10-K, July 14, 2026 |
| Reportable segments | 1 (period ending July 31, 2026) | 10-Q, September 14, 2026 |
| Latest proxy statement | Meeting September 9, 2026 (filed July 28, 2026) | DEF 14A, July 28, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Irvine, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 3, 2026 | Timothy P. Moran Chief Business Officer | Sale | 3,192 | $94K | Form 4, November 5, 2026 |
| October 29, 2026 | Vaseem Mahboob Chief Financial Officer | Sale | 79,500 | $2.4M | Form 4, October 29, 2026 |
| October 27, 2026 | Traci S. Umberger See Remarks | Sale | 30,000 | $901K | Form 4, October 29, 2026 |
| October 21, 2026 | Traci S. Umberger See Remarks | Sale | 100,000 | $2.7M | Form 4, October 22, 2026 |
| October 20, 2026 | Brian Daniel Webster See Remarks | Sale | 15,000 | $443K | Form 4, October 22, 2026 |
| September 30, 2026 | Raymond W. Cohen Director | Sale | 3,330 | $98K | Form 4, October 1, 2026 |
| September 21, 2026 | Elizabeth Kwo Director | Sale | 4,010 | $97K | Form 4, September 23, 2026 |
| September 8, 2026 | Conor Hanley Director | Sale | 5,694 | $144K | Form 4, September 10, 2026 |
Recent 8-K events
- 8-K filed 2026-09-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-10
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-07-14
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-03-17
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-04
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2025-12-01
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-10
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-09-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-04
- Item 5.07 Submission of matters to a vote of security holders
Frequently asked questions about Kestra Medical Technologies, Ltd.
- What does Kestra Medical Technologies, Ltd. do?
- In its own words, from Item 1 of its 10-K: "We are a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. We have developed and are commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (“SCA”) during vulnerable periods of recovery."
- What is Kestra Medical Technologies, Ltd.'s revenue?
- $95.1M for the fiscal year ending April 30, 2026, from its 10-K filed July 14, 2026.
- Is Kestra Medical Technologies, Ltd. profitable?
- Kestra Medical Technologies, Ltd. reported net income of -$132M for the fiscal year ending April 30, 2026.
- How many employees does Kestra Medical Technologies, Ltd. have?
- About 443 as of April 30, 2026, as stated in its annual report.
- Who is the CEO of Kestra Medical Technologies, Ltd.?
- Brian Webster, President and Chief Executive Officer, as named in a 10-Q filed September 14, 2026.
- Who is the CFO of Kestra Medical Technologies, Ltd.?
- Vaseem Mahboob, Chief Financial Officer, as named in a 4 filed August 11, 2026.
- Where is Kestra Medical Technologies, Ltd. headquartered?
- Kirkland, WA.
- What is Kestra Medical Technologies, Ltd.'s stock ticker?
- KMTS on Nasdaq.
- What industry is Kestra Medical Technologies, Ltd. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Kestra Medical Technologies, Ltd.'s website?
- kestramedical.com. Investor relations: https://investors.kestramedical.com/news-events/news-releases.
- When does Kestra Medical Technologies, Ltd. report earnings next?
- December 10, 2026. Source: pg_future_events.
- Is Kestra Medical Technologies, Ltd. a public company?
- Yes. Kestra Medical Technologies, Ltd. files with the SEC under CIK 0001877184 and trades as KMTS.
- Who audits Kestra Medical Technologies, Ltd.?
- PricewaterhouseCoopers LLP, Irvine, California, as named in its latest annual report (10-K).
- How many shares of Kestra Medical Technologies, Ltd. are outstanding?
- 59.6 million shares as of September 11, 2026, from its 10-Q filed September 14, 2026.
- What is Kestra Medical Technologies, Ltd.'s public float?
- $619M as of October 31, 2025, as reported on the cover of its 10-K filed July 14, 2026.
- How many business segments does Kestra Medical Technologies, Ltd. report?
- 1 reportable segment for the period ending July 31, 2026, from its 10-Q filed September 14, 2026.
- When is Kestra Medical Technologies, Ltd.'s annual shareholder meeting?
- September 9, 2026, per its proxy statement (DEF 14A) filed July 28, 2026.
- Have Kestra Medical Technologies, Ltd. insiders traded stock recently?
- Since March 7, 2025, officers and directors reported 31 open-market sales worth about $15.5M and 2 purchases worth about $489K on Forms 4 and 5. The most recent: Timothy P. Moran (Chief Business Officer) sold 3,192 shares on November 3, 2026.